Device Trial Radar · NCT06674369
Ongoing Effect of Expansion Prisms Following the Discontinuation of Use on Visual Field Enlargement and Retrograde Ganglion Cell Degeneration in Homonymous Hemianopia Patients
Last checked: Nov 20, 2026Latest source record: Nov 5, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
15
Actual
Start
Aug 28, 2022
Primary completion
Oct 18, 2022
Study completion Oct 30, 2024
Sponsor
- Lead sponsor
- Okan UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Ankara University
- First posted
- Nov 5, 2024
Design
- Study type
- Observational
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 months, up to 55 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this observational study is to learn about the long-term effects of Pelli prism in Hemianopia patients who take Prisms for awareness of the area they cannot see. The main question it aims to answer is: Does the field enlargement observed with the prism continues after the prism is removed? Participants already using Peli prisms as part of their regular medical care for Hemianopia, in the upcoming routine controls their field of vision enlargements will be examined.
Conditions
- Homonymous Hemianopsia
Interventions
Peli prism for hemianopiaDevice
Peli prism uses high-powered prisms (40 Dioptre) that expand a hemianopic patient's awareness of their blind side. This awareness enables patients to better detect obstacles and navigate around them. Effect of the prism considered as temporary We investigated whether the effect persists after the prism is removed.To understand the persistence of the effect, we examined the changes in the visual field with CVF (Computerized visual field examination)before the prism was applied, with the prism and 1 week after the prism was removed.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Computerised visual field changesTime frame: From enrollment to the end of prism use at 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Okan University Hospital Ophthalmology clinic
Istanbul, Tuzla, Turkey (Türkiye)
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.